Cenicriviroc - Tobira Therapeutics

Drug Profile

Cenicriviroc - Tobira Therapeutics

Alternative Names: Cenicriviroc mesylate; CVC; TAK-652; TBR-652

Latest Information Update: 04 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institute for Health Research; Takeda
  • Developer Allergan; Dong-A ST; Imperial College of Science, Technology and Medicine; National Institute for Health Research; Tobira Therapeutics; University of Hawaii
  • Class Amides; Antifibrotics; Antineoplastics; Antiretrovirals; Imidazoles; Small molecules
  • Mechanism of Action CCR2 receptor antagonists; CCR5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-alcoholic steatohepatitis
  • Phase II Cognition disorders; HIV-1 infections; Non-alcoholic fatty liver disease; Primary sclerosing cholangitis
  • Phase I Liver disorders
  • Preclinical Cholestasis; Diabetic nephropathies
  • No development reported Cancer; Graft-versus-host disease

Most Recent Events

  • 07 May 2018 Novartis Pharmaceuticals plans the TANDEM phase II trial for Non-alcoholic Steatohepatitis in July 2018 , (NCT03517540)
  • 17 Dec 2017 Allergan completes a phase I trial in Liver disorders in USA (PO) (NCT03376841)
  • 10 Nov 2017 Tobira Therapeutics completes the phase IIb CENTAUR trial for Non-alcoholic steatohepatitis in Australia, Belgium, France, Germany, Hong Kong, Italy, Moldova, Poland, Spain, USA and United Kingdom (PO) (NCT02217475)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top